Integra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual Meeting

Integra LifeSciences (IART) will showcase its ear, nose and throat portfolio at the AAO-HNSF Annual Meeting, October 17–20 in Los Angeles.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Integra LifeSciences (IART) will showcase its ear, nose and throat portfolio at the AAO-HNSF Annual Meeting, October 17–20 in Los Angeles. Integra also sponsors the Otosclerosis Study Group, where Seilesh C. Babu will present investigator-initiated research on October 17. The study examines Eustachian tube balloon dilation performed alongside surgery for chronic ear disease. Attendees can visit Booth 1400 for ACCLARENT AERA training and certification.

Key Terms

investigator-initiated study, eustachian tube balloon dilation, fda clearance

3 terms

investigator-initiated study medical

"The investigator-initiated study examines the impact of Eustachian tube balloon dilation"

An investigator-initiated study is a clinical or observational research project designed and run by independent researchers or clinicians rather than a company that makes the drug or device being tested. For investors, these studies act like an independent test drive: they can produce credible, additional evidence about safety, effectiveness or new uses that may change market expectations, influence prescribing, regulatory decisions, or the commercial value of a product.

eustachian tube balloon dilation medical

"The investigator-initiated study examines the impact of Eustachian tube balloon dilation"

A minimally invasive medical procedure that widens the Eustachian tube (the narrow channel connecting the middle ear to the back of the nose) by inserting and inflating a small balloon inside the tube to stretch its walls and improve airflow and drainage. It is done under visualization with endoscopic guidance and typically aims to relieve chronic Eustachian tube dysfunction; the balloon does not remove tissue but dilates the existing passage, and results may vary by patient and condition severity.

fda clearance regulatory

"ACCLARENT AERA received FDA clearance for its pediatric indication"

FDA clearance is the U.S. Food and Drug Administration’s official permission to market certain medical devices or diagnostic tests after reviewing evidence that they are as safe and effective as similar products already on the market. For investors, it’s like a product passing a required safety inspection — it reduces regulatory uncertainty, speeds commercial rollout, and can directly affect sales prospects, valuation, and partnership opportunities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

10/16/2026 - 08:39 AM EDT

PRINCETON, N.J., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced its participation in the 2026 American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting & OTO EXPO, taking place October 17-20 in Los Angeles, California.

At this year's meeting, Integra will showcase its growing portfolio of ENT technologies and instruments, including the ACCLARENT AERA® Eustachian Tube Treatment, TruDi® Navigation System, MicroFrance® ENT and Laparoscopy Instruments, Bien-Air® Drill and Shaver Systems and RELIEVA SPINPLUS® Balloon Sinuplasty System.

Additionally, Integra is a sponsor of the Otosclerosis Study Group. As part of the Otosclerosis Study Group, Seilesh C. Babu, M.D., president of Michigan Ear Institute and associate professor at Wayne State University, will present new clinical research entitled "The Effects of Concurrent Eustachian Tube Balloon Dilation on Surgical Outcomes in Chronic Ear Disease" (Poster #890) on October 17^th. The investigator-initiated study examines the impact of Eustachian tube balloon dilation when performed alongside surgery for chronic ear disease.

"Chronic ear disease can significantly affect hearing, quality of life and long-term patient outcomes, while often presenting complex treatment challenges for physicians," said Chris Schutt, M.D., vice president, Operations & Excellence, Office of the Chief Medical Officer, Integra LifeSciences. "As our understanding of the underlying factors that contribute to chronic ear disease continues to evolve, there is growing interest in approaches that address root causes while supporting long-term outcomes. We remain committed to advancing clinical evidence, education and innovation across ENT care and are pleased to support new research."

Conference attendees are invited to visit Integra LifeSciences at Booth 1400 to learn more about the company's growing ENT portfolio and participate in hands-on ACCLARENT AERA training and certification.

ACCLARENT AERA received FDA clearance for its pediatric indication in December 2023, becoming the first and only Eustachian Tube Balloon Dilation System indicated for pediatric patients ages eight and older.¹

In addition to showcasing AERA, Integra will highlight solutions across the ENT continuum, including navigation, powered instrumentation and surgical instruments intended to help physicians treat and manage a broad range of ENT conditions.

About Integra LifeSciences

Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care. For the latest news and information about Integra LifeSciences and its products, please visit www.integralife.com.

About ACCLARENT AERA® Eustachian Tube Balloon Dilation System

The ACCLARENT AERA Eustachian Tube Balloon Dilation System is intended to dilate the Eustachian tube for treatment of persistent Eustachian tube dysfunction in patients ages 18 and older. For patients ages 8-17 years, the ACCLARENT AERA Eustachian Tube Balloon Dilation System, alone or in combination with adjunctive procedures, is intended to treat patients with objective signs of persistent obstructive Eustachian tube dysfunction from inflammatory pathology, resulting in chronic otitis media with effusion and are refractory to at least one surgical intervention for persistent obstructive Eustachian tube dysfunction.

Investor Relations Contact:
Chris Ward
(609) 772-7736
chris.ward@integralife.com

Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com

____________________________
¹ U.S. Food and Drug Administration. ACCLARENT AERA Eustachian Tube Dilation System (K230742). Dec. 13, 2023. Website: FDA 510(k) Clearance Database - ACCLARENT AERA K230742 [accessdata.fda.gov]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d25cf2e9-3e7c-4a2c-bde1-652b6c681ec8